Cara Therapeutics Inc (CARA)
0.3279
-0.01
(-3.84%)
USD |
NASDAQ |
Nov 13, 16:00
0.3278
0.00 (0.00%)
After-Hours: 20:00
Cara Therapeutics Research and Development Expense (Quarterly): 9.308M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 9.308M |
| March 31, 2024 | 21.96M |
| December 31, 2023 | 28.42M |
| September 30, 2023 | 25.45M |
| June 30, 2023 | 30.31M |
| March 31, 2023 | 24.33M |
| December 31, 2022 | 26.01M |
| September 30, 2022 | 24.69M |
| June 30, 2022 | 19.90M |
| March 31, 2022 | 21.27M |
| December 31, 2021 | 22.83M |
| September 30, 2021 | 15.51M |
| June 30, 2021 | 25.22M |
| March 31, 2021 | 19.13M |
| December 31, 2020 | 27.14M |
| September 30, 2020 | 21.07M |
| June 30, 2020 | 26.11M |
| March 31, 2020 | 33.54M |
| December 31, 2019 | 29.86M |
| September 30, 2019 | 35.99M |
| June 30, 2019 | 24.36M |
| March 31, 2019 | 23.61M |
| December 31, 2018 | 22.80M |
| September 30, 2018 | 22.30M |
| Date | Value |
|---|---|
| June 30, 2018 | 17.00M |
| March 31, 2018 | 13.43M |
| December 31, 2017 | 11.58M |
| September 30, 2017 | 9.151M |
| June 30, 2017 | 6.961M |
| March 31, 2017 | 20.84M |
| December 31, 2016 | 20.28M |
| September 30, 2016 | 9.671M |
| June 30, 2016 | 10.76M |
| March 31, 2016 | 8.546M |
| December 31, 2015 | 7.568M |
| September 30, 2015 | 5.584M |
| June 30, 2015 | 4.684M |
| March 31, 2015 | 3.385M |
| December 31, 2014 | 3.459M |
| September 30, 2014 | 6.208M |
| June 30, 2014 | 3.20M |
| March 31, 2014 | 2.201M |
| December 31, 2013 | 1.978M |
| September 30, 2013 | 3.764M |
| June 30, 2013 | 2.021M |
| March 31, 2013 | 0.922M |
| December 31, 2012 | 1.023M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
9.308M
Minimum
Jun 2024
33.54M
Maximum
Mar 2020
23.79M
Average
24.69M
Median
Sep 2022
Research and Development Expense (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 9.275M |
| Alaunos Therapeutics Inc | 0.18M |
| Oragenics Inc | 0.9068M |
| Cocrystal Pharma Inc | 4.308M |
| Citius Pharmaceuticals Inc | 2.764M |